Immuneering’s midstage pancreatic deep cyclic MEK protein inhibitor, (DCI), almost doubled the standard overall survival. It is a deep cycle inhibitor that targets key pathways in a pulsed manner. Results of its pancreatic trial, as was reported by BioSpace, included Truists Financial Corporation’s cautionary comments that there are certain unknowns in the data.
As an example, the fact that atebimetinib uses pulsing action rather than the sustained inhibition of some of the MEK blockers. Therefore, atebirmetinib’s results are slower but have more durable activity against the tumors.
The Results
Results showed an 86% OS rate of nine months for patients treated with atebimetinib and gemcitabine/nab-paclitaxel first-line therapy as opposed to 47% at the same time point for patients treated with standard of care.
Plans are to begin a registrational study by year’s end and start dosing by mid-2026.
The company expects to start additional trial combination arms for atebimetinib, including in non-small cell lung cancer.
